Pharmalot By Ed Silverman Race is often overlooked in key clinical trial data used to win new drug approvals in Europe
Pharmalot By Ed Silverman FDA warns Miami University contract testing lab over falsified data, poor quality control
Pharmalot By Ed Silverman Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver
Pharmalot By Ed Silverman A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO
First Opinion By Els Torreele Global health should not be determined by pharma investors and shareholders
Pharmalot By Ed Silverman Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels
Pharmalot By Ed Silverman Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process
Pharmalot By Ed Silverman U.N. committee urges wealthy nations to honor human rights and widen access to Covid vaccines
Pharmalot By Ed Silverman Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members
Pharmalot By Ed Silverman U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency
Pharmalot By Ed Silverman Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
Pharma By Ed Silverman The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
Pharmalot By Ed Silverman California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
Pharmalot By Ed Silverman Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing
Pharma By Ed Silverman Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices
Pharmalot By Ed Silverman Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims
Pharma By Ed Silverman Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law
Pharmalot By Ed Silverman Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?
Pharmalot By Ed Silverman Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review
Pharmalot By Ed Silverman One in four pharma status reports on follow-up trials are late or aren’t filed
Pharmalot By Ed Silverman Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients
Pharmalot By Ed Silverman Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms
Pharmalot By Ed Silverman Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging
Pharmalot By Ed Silverman U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Pharmalot By Ed Silverman Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions